Trastuzumab in metastatic breast cancer

European Journal of Gynaecological Oncology

Volumn 27, Issue 3, 2006, Pages 247-249

  Tomao, F ^a   Miele, E ^a   Spinelli, G P ^a   Russillo, M ^a   La Ferla, G ^b   Tomao, S ^b,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b CANCER RESEARCH AND PREVENTION INSTITUTE ISPO   (Italy)

^c NONE   (Italy)

Author keywords

HER2; Metastatic breast cancer; Trastuzumab

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CAPECITABINE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLUOROURACIL DERIVATIVE; MONOCLONAL ANTIBODY; NAVELBINE; TAXANE DERIVATIVE; TRASTUZUMAB;

ANAPHYLAXIS; ANEMIA; ANGIONEUROTIC EDEMA; ARTICLE; BREAST CANCER; BRONCHOSPASM; CHEMOTHERAPY; DRUG HYPERSENSITIVITY; DYSPNEA; GENE OVEREXPRESSION; HORMONAL THERAPY; HUMAN; HYPERSENSITIVITY REACTION; HYPOTENSION; LEUKOPENIA; LUNG TOXICITY; METASTASIS; TACHYCARDIA; URTICARIA;

EID: 33745458662     PISSN: 03922936     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Chazin et al.: "Transformation mediated by the human HER-2 gene independent of epidermal growth factor receptor". Oncogene, 1992, 7, 1859.
2. Heldin C.H.: "Dimerization of cell surface receptors in signal transduction". Cell, 1995, 80, 213.
3. Blume-Jensen P., Hunter T.: "Oncogene kinase signalling". Nature, 2001, 411, 355.
4. Slamon DJ. et al.: "Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene". Science, 1987, 235, 177.
5. Slamon D.J. et al.: "Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer". Science, 1989, 244, 707.
6. Jiminez R.E. et al.: "Determination of HER-2/neu status in breast carcinoma: Comparative analysis of immunohistochemistry and fluorescent in situ hybridization". Mod. Pathol., 2000, 13, 37.
7. Lebeau A. et al.: "HER/neu analysis in archival tissue samples of human breast cancer: Comparison of immunohistochemistry and fluorescence in situ hybridisation". J. Clin. Oncol., 2001, 19, 354.
8. Wang S. et al.: "Laboratory assessment of the status of HER-2/neu protein and oncogene in breast cancer specimens: Comparison of immunoistochemestry assay with fluorescence in situ hybridization assays". J. Clin. Pathol., 2000, 53, 374.
9. Bast R.C. et al.: "American Oncology Tumor Markers Expert Panel: 2000 update of recommendations for the use of tumor markers in breast and colorectal cancerar: Clinical practice guidelines of the American Society of Clinical Oncology". J. Clin. Oncol., 2001, 19, 1865.
10. Schneider J.W. et al.: "Trastuzumab cardiotoxicity: speculations regarding pathophysiology and targets for further study". Semin. Oncol., 2002, 29, 3 (suppl. 11), 22.
11. Lee K.F. et al.: "Requirement for neureguling receptor HER-2/erbB2 in neural and cardiac development". Nature, 1995, 378, 394.
12. Cobleigh M., Vogel C. et al.: "Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease". J. Clin. Oncol., 1999, 17, 2639.
13. Vogell C., Cobleigh M. et al.: "Efficacy and safety of trastuzumab as a single agent in first line treatment of HER2-overexpressing metastatic breast cancer". J. Clin. Oncol., 2002, 20, 719.
14. Konecnyg et al.: "Therapeutic advantage of chemotherapy drugs in combination with Herceptin against human breast cancer cells with HER-2/neu overexpression" (abstract). Breast Cancer Res. Treat., 1999, 57, 114.
15. Chou T.C., Talay P.: "Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs or enzyme inhibitors". Adv. Enzyme Regul., 1984, 22, 27.
16. Burstein H. et al.: "Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer". J. Clin. Oncol., 2001, 19, 2722.
17. Seidman A.D. et al.: "HER-2/neu over-expression and clinical taxane sensitivity: a multivariate analysis in patients with metastatic breast cancer (MBC)". Proc. Am. Soc. Clin. Oncol., 1996, 75, 104.
18. Uber K. et al.: "A phase II trial of weekly docetaxel and herceptin as first- or second-line treatment in HER2 over-expressing metastatic breast cancer" (abstract). Proc. Am. Soc. Clin. Oncol., 20, 50b, 201.
19. Bums H.: "Docetaxel (Taxotere) plus trastuzumab (Herceptin) in breast cancer". Semin. Oncol., 2001, 28, 38.
20. Bangemann N. et al.: "Treatment of HER2 overexpressing metastatic breast cancer with trastuzumab and chemotherapy" (abstract). Breast Cancer Res. Treat., 2000, 64, 23.
21. Bangemann N. et al.: "Capecitabine combined with trastuzumab in the therapy of intensively pretreated HER2-overexpressing metastatic breast cancer (MBC)" (abstract). Ann. Oncol., 2000, 11 (suppl. 4), 143.